Analysis of serial ovarian volume measurements and incidence of ovarian cancer: Implications for pathogenesis

Journal of the National Cancer Institute

Volumn 106, Issue 10, 2014, Pages

  Bodelon, Clara ^a   Pfeiffer, Ruth M ^a   Buys, Saundra S ^c   Black, Amanda ^a   Sherman, Mark E ^a,b  

^a Bethesda   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; FEMALE GENITAL TRACT PARAMETERS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; OVARIAN VISUALIZATION; OVARIAN VOLUME; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; SERIAL OVARIAN VOLUME MEASUREMENT; TIME; BLOOD; CASE CONTROL STUDY; EARLY DIAGNOSIS; ECHOGRAPHY; MASS SCREENING; METHODOLOGY; MIDDLE AGED; ORGAN SIZE; OVARY; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK; VAGINA;

AGED; CA-125 ANTIGEN; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; ODDS RATIO; ORGAN SIZE; OVARIAN NEOPLASMS; OVARY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY; VAGINA;

EID: 84984991414     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju262     Document Type: Article

References (35)

1. ACS. Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2013.
2. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295-2303.
3. Menon U, Skates SJ, Lewis S, et al. Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. J Clin Oncol. 2005;23(31):7919-7926.
4. van Nagell JR Jr., DePriest PD, Ueland FR, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007;109(9):1887-1896.
5. Lu KH, Skates S, Hernandez MA, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119(19):3454-3461.
6. Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer. 2008;18(3):414-420.
7. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42(7):918-931.
8. Perets R, Wyant Gregory A, Muto Katherine W, et al. Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. Cancer Cell. 2013;24(6):751-765.
9. Sherman ME, Piedmonte M, Mai PL, et al. Pathologic Findings in Risk-Reducing Salpingo-Oophorectomy (RRSO): Primary Results from Gynecologic Oncology Group Trial GOG-0199. Submitted 2013.
10. Yates MS, Meyer LA, Deavers MT, et al. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCAassociated tumorigenesis. Cancer Prev Res (Phila). 2011;4(3):463-470.
11. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113(4):775-782.
12. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 Suppl):273S-309S.
13. Sample WF, Lippe BM, Gyepes MT. Gray-Scale Ultrasonography of the Normal Female Pelvis. Radiology. 1977;125(2):477-483.
14. Campbell S, Goessens L, Goswamy R, et al. Real-time ultrasonography for determination of ovarian morphology and volume. A possible early screening test for ovarian cancer? Lancet. 1982;1(8269):425-426.
15. Higgins RV, van Nagell JR Jr., Woods CH, et al. Interobserver variation in ovarian measurements using transvaginal sonography. Gynecologic Oncology. 1990;39(1):69-71.
16. Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trial.s 2000;21(6 Suppl):349S-355S.
17. Percy C, Van Holten V, Muir C. International Classification of Diseases for Oncology. Second ed: World Health Organization; 1990.
18. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526.
19. Cleveland WS. Robust Locally Weighted Regression and Smoothing Scatterplots. Journal of the American Statistical Association. 1979;74(368):829-836.
20. Killick R, Fearnhead P, Eckley IA. Optimal Detection of Changepoints With a Linear Computational Cost. Journal of the American Statistical Association. 2012;107(500):1590-1598.
21. Pfeiffer RM, Bur E. A Model Free Approach to Combining Biomarkers. Biom J. 2008;50(4):558-570.
22. Brown PO, Palmer C. The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection. PLoS Med. 2009;6(7):e1000114.
23. Havrilesky LJ, Sanders GD, Kulasingam S, et al. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol. 2008;111(2):179-187.
24. Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012;13(3):285-291.
25. Sharma A, Burnell M, Gentry-Maharaj A, et al. Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound Obstet Gynecol. 2013;42(4):472-477.
26. Bell RJ, Healy DL, Robertson DM, et al. Ovarian status in healthy postmenopausal women: follow-up 12 months after transvaginal ultrasound. Menopause. 2009;16(6):1149-1155.
27. van Nagell JR Jr., DePriest PD, Reedy MB, et al. The Efficacy of Transvaginal Sonographic Screening in Asymptomatic Women at Risk for Ovarian Cancer. Gynecologic Oncology. 2000;77(3):350-356.
28. Sherman ME, Lacey JV, Buys SS, et al. Ovarian Volume: Determinants and Associations with Cancer among Postmenopausal Women. Cancer Epidemiology Biomarkers & Prevention. 2006;15(8):1550-1554.
29. Sherman ME, Madigan MP, Lacey JV Jr., et al. Ovarian volumes among women with endometrial carcinoma: Associations with risk factors and serum hormones. Gynecologic Oncology. 2007;107(3):431-435.
30. Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to riskreducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol. 2011;204(1):19.e1-19.e6.
31. Kwon JS, Tinker A, Pansegrau G, et al. Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. Obstet Gynecol. 2013;121(1):14-24.
32. Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010;102(1):26-38.
33. Pinsky PF, Zhu C, Skates SJ, et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer. 2013;132(9):2127-2133.
34. Lutz AM, Willmann JK, Drescher CW, et al. Early Diagnosis of Ovarian Carcinoma: Is a Solution in Sight? Radiology. 2011;259(2):329-345.
35. Chan A, Gilks B, Kwon J, et al. New Insights Into the Pathogenesis of Ovarian Carcinoma: Time to Rethink Ovarian Cancer Screening. Obstet Gynecol. 2012;120(4):935-940.